Slide 1: Investor Presentation: Q1 FY25 Business Update
Investor Presentation Althea Group Holdings Q1 FY25 Business Update Ticker: AGH:ASX Date: 31 October 2024
Slide 2: Introduction
Introduction In our recent September quarterly results, we demonstrated strong momentum and resilience in a competitive market. This presentation highlights our financial performance, key operational achievements, and strategic initiatives that position us for continued growth. As we move forward, o
Slide 3: Financial Highlights
Financial Highlights REVENUE CASH FLOW FY25 GUIDANCE REFINED & REAFFIRMED $8.3m Positive Operating Revenue of cash flow of (unaudited) $50m – $57m Driven by record $304,000 EBITDA between recreational cannabis revenue of $6.2 million supported by cost-saving initiatives $4m – $5.5m and pharmaceutica
Slide 4: Key Operational Achievements
Key Operational Achievements MyAccess Clinics Business Cost Reduction Program Divestment US Expansion • On track to deliver $4.0 • Sold for $1.0 million, cutting • New emulsion lab in million in annualised savings. $1.5 million in annual costs Florida, joint venture with and improving focus on core
Slide 5: Peak Canada Recreational Cannabis Highlights
Peak Canada Recreational Cannabis Highlights
Slide 6: Peak Canada – Recreational Cannabis Growth Highlights
Recreational cannabis Peak Canada – Recreational Cannabis Growth Highlights Cannabis Beverage Production Product Diversification RECORD QUARTERLY • Record demand aligns with improved • Broad capabilities across multiple product lines: REVENUE production efficiencies. Growth is set to accelerate as P
Slide 7: Peak USA Expansion and Market Positioning
Peak USA Expansion and Market Positioning
Slide 8: Peak USA – Expansion and Market Positioning
Recreational cannabis Peak USA – Expansion and Market Positioning Peak USA Opportunity Production & Distribution Expansion US CANNABIS BEVERAGE MARKET GROWTH • Establishment of an emulsion lab in Florida for THC infusion consistency. Projected market growth at Product Launch with Flora Growth 54.3%
Slide 9: Althea Pharmaceutical Cannabis Performance
Althea Pharmaceutical Cannabis Performance
Slide 10: Althea – Pharmaceutical Cannabis Performance Highlights
Pharmaceutical cannabis Althea – Pharmaceutical Cannabis Performance Highlights Supply Chain Recovery QUARTERLY REVENUE • Transition to new suppliers completed, with improved pricing and reliable $2.1m stock flow expected to boost gross margins. Revenue Recovery and Growth • Full product availabilit
Slide 11: Strategic Initiatives
Strategic Initiatives COST REDUCTION SUCCESS DIVESTMENT FOCUS Annualised $4.0 million in savings Sale of MyAccess Clinics business for $1.0 from restructuring and operational million, reducing $1.5 million in annual costs efficiencies. and sharpening focus on core segments. MANAGEMENT ALIGNMENT GOVE
Slide 12: Focus on Shareholder Value
Focus on Shareholder Value Financial Optimisation • Positive cash flow from cost management, divestitures, and efficient capital allocation. Refined and Reaffirmed FY25 Guidance • Revenue of between $50 to 57 million with positive EBITDA of $4 to 5.5 million, with the financial results expected to b
Slide 13: Legal Disclaimer
Legal Disclaimer Althea Group Holdings Limited ACN 626 966 943 (Company) has prepared this presentation (Presentation) dated 31 October 2024 to provide current and prospective investors in the Company with an update in relation to the Company, its subsidiaries and their activities. The information i
Slide 14: Contact us
Althea Group Holdings Ltd Contact us Joshua Fegan CEO & Managing Director E: info@altheagroupholdings.com
Slide 15: Slide 15